Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Angioslide Announces the European Launch of New 300 mm Long Device Allowing Treatment of Entire Superficial Femoral Artery(SFA) with One Device

September 8, 2011

CAESAREA, Israel, September 8, 2011 /PRNewswire/ –

Angioslide Ltd. announces the first procedures with its new 5x300mm
PROTEUS device for treating the Superficial Femoral Artery (SFA). PROTEUS
technology combines a Percutaneous Transluminal Angioplasty (PTA) balloon
and embolic capture of particles in one device. The new 5×300 mm size joins
Angioslide’s current dedicated product line solutions for the lower limbs.

Initial treatments using the new PROTEUS device were conducted in
leading world centers, Parkkrankenhaus Leipzig and Herzzentrum Bad
Krozingen, located in Germany. The PROTEUS 5X300 mm makes it possible to
treat lesions up to 300 mm with one device, while providing an immediate
solution for embolic capture.

“Angioslide’s breakthrough technology, now available also in 300 mm
length as well, is a unique solution for lesions with high level of embolic
material, including Chronic Total Occlusions (CTO), in stent-restenosis,
thrombus containing lesions and post atherectomy PTA,” said Prof. Thomas
Zeller, Head of the Angiology Department, Heart Center Bad-Krozingen.

Prof. Dierk Scheinert, Head of the Department of Angiology,
Park-Krankenhaus Leipzig, adds, “We have been using the PROTEUS product line
as part of our daily practice for a few years, and are working closely with
the Angioslide team. I welcome the release of the 5X300 mm. We can now use
one device to treat patients with SFA diseases, which facilitates the
procedural flow and makes the intervention cost-effective.”

With the increase in life expectancy, diabetes prevalence, and number of
high-risk patients, together with the shift toward an “endovascular-first”
approach as a preferred procedure over surgical revascularization, there is
a growing need for expanding the current interventional “tool box” to
accommodate procedures designed specifically to treat long and diffuse
lesions in a quick and effective manner.

“We are committed to introducing new products to the market
continuously, addressing the growing range of endovascular solutions,” said
Lihu Avitov, Angioslide CEO. “With patients’ needs in mind, the 5X300 mm
device is the first in a series of long balloons, adding to our current
offering of 20-100 mm devices. The PROTEUS product family provides
additional confidence to clinicians treating their endovascular patients.”

The PROTEUS 5X300 mm is currently released for the European market only,
and is undergoing an evaluation regulatory process with the FDA.

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company
that developed a unique Embolic Capture Angioplasty solution, PROTEUS(TM),
which provides a combination of PTA balloon and embolic capture. The
PROTEUS(TM) device addresses an unmet need for an easy-to-use, efficient and
cost-effective embolic particle capture solution for the peripheral vascular
disease market. It is the first device of its kind to receive FDA clearance
for use in lower limbs. The device has also received European CE Mark
approval for lower limb use and is being marketed in selected regions in
Europe. Angioslide headquarters are located in Caesarea, Israel, with
regional offices in Europe and the US. For more information visit our
website at http://www.angioslide.com

        Contact:
        Shira Doron
        Marketing Director
        Mobile: +972-54-9011134
        Email:  shirad@angioslide.com

SOURCE Angioslide Ltd.


Source: PR Newswire